BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) and Merck’s Zepatier elbasvir/grazoprevir; colorectal cancer therapy Elunate fruquintinib...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...Fibroblast growth factor receptor 1 Jonathan Block and Paul Bonanos, Associate Editor minocycline foam (FMX103) Elunate, fruquintinib (HMPL-013) RGX-314 Opsumit...
BioCentury | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

...$12.23 (11%) to $95.22 on Tuesday. Consensus figures provided by FactSet. BioCentury Staff Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide Elunate, fruquintinib (HMPL-013) LGD-6972...
BioCentury | Apr 15, 2019
Financial News

Chi-Med planning Hong Kong listing

...listing in 3Q19; terms have yet to be announced. In November 2018, Chi-Med launched Elunate fruquintinib...
...were off 50p to 4,700p in London Monday, but gained $0.16 to $31.36 on NASDAQ. Fruquintinib...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 7, 2018
Company News

Chi-Med, Innovent enter global cancer partnership

...advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib...
...mAb, is under review in China to treat relapsed or refractory classical Hodgkin lymphoma. Elunate fruquintinib...
...LSE:HCM; NASDAQ:HCM), Hong Kong, China Innovent Biologics Inc. (HKSE:1801), Suzhou, China Business: Cancer Alicia Parker Elunate, fruquintinib (HMPL-013) sintilimab...
BioCentury | Nov 30, 2018
Company News

Chi-Med, Innovent enter global cancer partnership

...advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib...
...mAb, is under review in China to treat relapsed or refractory classical Hodgkin lymphoma. Elunate fruquintinib...
...Co. (NYSE:LLY), which has Chinese rights to Elunate, is co-developing sintilimab with Innovent. Alicia Parker Elunate, fruquintinib (HMPL-013) sintilimab...
BioCentury | Nov 30, 2018
Clinical News

Chi-Med's fruquintinib misses OS endpoint in Phase III for third-line NSCLC

...Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of...
...Christian Hogg told BioCentury in September that the company planned to submit an NDA for fruquintinib...
...disease control rate (DCR) and duration of response Status: Phase III data Milestone: NA Chris Lieu fruquintinib (HMPL-013) Eli...
BioCentury | Nov 16, 2018
Clinical News

Chi-Med down on fruquintinib OS miss in third-line NSCLC

...Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of...
...Christian Hogg told BioCentury in September that the company planned to submit an NDA for fruquintinib...
...are partnered for the inhibitor of VEGF receptors 1, 2 and 3 in China. Chris Lieu fruquintinib (HMPL-013) Eli...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...NDA 4Q18 Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) / Eli Lilly and Co. (NYSE:LLY) Elunate fruquintinib...
Items per page:
1 - 10 of 58